Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 12
1999 21
2000 50
2001 72
2002 145
2003 134
2004 128
2005 226
2006 233
2007 317
2008 394
2009 359
2010 311
2011 308
2012 157
2013 14
2014 21
2015 26
2016 44
2017 35
2018 25
2019 13
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2,743 results
Results by year
Filters applied: . Clear all
Page 1
Endocannabinoid System: A Multi-Facet Therapeutic Target
Kaur R, et al. Curr Clin Pharmacol 2016 - Review. PMID 27086601
Presently, cannabinoid receptor agonists like nabilone and dronabinol are used for reducing the chemotherapy induced vomiting. ...Another angle to be introspected for therapeutic abilities of this group of drugs is non-CB1 and non-CB2 receptor targets for cannabinoids. ...
Presently, cannabinoid receptor agonists like nabilone and dronabinol are used for reducing the chemotherapy induced vomiting. …
Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
Khurana L, et al. Neuropharmacology 2017 - Review. PMID 28527758 Free PMC article.
The identification of allosteric modulators of the cannabinoid receptor 1 (CB(1)) has given a new direction to the development of cannabinoid-based therapeutics due to the many advantages offered by targeting allosteric site(s). Allosteric receptor modulators hold potential to develop subtype-specific and pathway-specific therapeutics. Here we briefly discuss the first-generation of allosteric modulators of CB(1) receptor, their structure-activity relationships, signaling pathways and the allosteric binding site(s) on the CB(1) receptor. ...
The identification of allosteric modulators of the cannabinoid receptor 1 (CB(1)) has given a new direction to the deve …
The Endocannabinoid System and its Modulation by Phytocannabinoids
Di Marzo V and Piscitelli F. Neurotherapeutics 2015 - Review. PMID 26271952 Free PMC article.
The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ(9)-tetrahydrocannabinol (but not for most other plant cannabinoids or phytocannabinoids)-cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R); their two most studied endogenous ligands, the "endocannabinoids" N-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG); and the enzymes responsible for endocannabinoid metabolism. ...Finally, some of the metabolic enzymes may also participate in the chemical modification of molecules that have very little to do with endocannabinoid and cannabinoid targets. ...
The endocannabinoid system is currently defined as the ensemble of the two 7-transmembrane-domain and G protein-coupled receptors for Δ(9)-t …
The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.
Donvito G, et al. Neuropsychopharmacology 2018 - Review. PMID 28857069 Free PMC article.
Notably, cannabinoid receptor agonists as well as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase produce reliable antinociceptive effects, and offer opioid-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain models. Emerging clinical studies show that 'medicinal' cannabis or cannabinoid-based medications relieve pain in human diseases such as cancer, multiple sclerosis, and fibromyalgia. ...
Notably, cannabinoid receptor agonists as well as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase …
Endocannabinoid system in neurodegenerative disorders
Basavarajappa BS, et al. J Neurochem 2017 - Review. PMID 28608560 Free PMC article.
The endocannabinoid system, which involves cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), endogenous cannabinoids and the enzymes that catabolize these compounds, has been shown to contribute to the development of NDDs in several animal models and human studies. ...
The endocannabinoid system, which involves cannabinoid receptors type 1 (CB1R) and type 2 (CB2R), endogenous cannabinoids and …
Cannabinoids in depressive disorders.
Poleszak E, et al. Life Sci 2018 - Review. PMID 30290188
Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others have been suggested. ...Responses to the cannabinoid agents are relatively fast, and most probably, the noradrenergic, serotoninergic, glutamatergic neurotransmission, neuroprotective activity, as well as modulation of the hypothalamic-pituitary-adrenal axis are implicated in the observed effects. ...
Benefits from use of cannabinoid agents in epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and others have be …
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.
Laprairie RB, et al. Br J Pharmacol 2015. PMID 26218440 Free PMC article.
BACKGROUND AND PURPOSE: Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB1 receptors. ...The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB1 receptor. ...
BACKGROUND AND PURPOSE: Cannabidiol has been reported to act as an antagonist at cannabinoid CB1 receptors. We hypothesized that cann …
Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders.
Manera C, et al. Recent Pat CNS Drug Discov 2016 - Review. PMID 27193072
RESULTS: During past years, cannabinoid CB1 and CB2 receptor ligands from plants or lab were rapidly developed and then various new structures were reported to be cannabinoids. ...On the contrary the development of CB2 receptor ligands has been more productive. Furthermore peripherally restricted agonists as well as CB1 receptor positive or negative allosteric modulators were studied with the aim of eliminating the undesirable CB1 receptor central effects. ...
RESULTS: During past years, cannabinoid CB1 and CB2 receptor ligands from plants or lab were rapidly developed and then variou …
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.
McPartland JM, et al. Br J Pharmacol 2015 - Review. PMID 25257544 Free PMC article.
Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant. ...They exhibit markedly disparate pharmacological profiles particularly at CB1 receptors: CBD is a very low-affinity CB1 ligand that can nevertheless affect CB1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB1 receptor antagonism. ...
Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoi
Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.
Hill MN, et al. Neuropsychopharmacology 2018 - Review. PMID 28745306 Free PMC article.
In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, there has been a surge of public and research interest in the role of cannabinoids in the regulation of stress-related biological processes and in their potential therapeutic application for stress-related psychopathology. Here we review the current state of knowledge regarding the effects of cannabis and cannabinoids in PTSD and the preclinical and clinical literature on the effects of cannabinoids and endogenous cannabinoid signaling systems in the regulation of biological processes related to the pathogenesis of PTSD. ...
In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, there has been a surge …
2,743 results
Jump to page
Feedback